Nektar Therapeutics Revenue 2006-2018 | NKTR

Nektar Therapeutics annual/quarterly revenue history and growth rate from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Nektar Therapeutics revenue for the quarter ending December 31, 2018 was $0.040B, a 58.28% decline year-over-year.
  • Nektar Therapeutics revenue for the twelve months ending December 31, 2018 was $1.193B, a 287.81% increase year-over-year.
  • Nektar Therapeutics annual revenue for 2018 was $1.193B, a 287.81% increase from 2017.
  • Nektar Therapeutics annual revenue for 2017 was $0.308B, a 86% increase from 2016.
  • Nektar Therapeutics annual revenue for 2016 was $0.165B, a 28.32% decline from 2015.
Nektar Therapeutics Annual Revenue
(Millions of US $)
2018 $1,193
2017 $308
2016 $165
2015 $231
2014 $201
2013 $149
2012 $81
2011 $71
2010 $159
2009 $72
2008 $90
2007 $273
2006 $218
2005 $126
Nektar Therapeutics Quarterly Revenue
(Millions of US $)
Q4 2018 $40
Q3 2018 $28
Q2 2018 $1,088
Q1 2018 $38
Q4 2017 $95
Q3 2017 $153
Q2 2017 $35
Q1 2017 $25
Q4 2016 $37
Q3 2016 $36
Q2 2016 $33
Q1 2016 $59
Q4 2015 $39
Q3 2015 $60
Q2 2015 $23
Q1 2015 $109
Q4 2014 $20
Q3 2014 $133
Q2 2014 $29
Q1 2014 $20
Q4 2013 $31
Q3 2013 $61
Q2 2013 $34
Q1 2013 $23
Q4 2012 $21
Q3 2012 $18
Q2 2012 $24
Q1 2012 $18
Q4 2011 $16
Q3 2011 $27
Q2 2011 $17
Q1 2011 $11
Q4 2010 $45
Q3 2010 $38
Q2 2010 $43
Q1 2010 $33
Q4 2009 $39
Q3 2009 $10
Q2 2009 $13
Q1 2009 $10
Q4 2008 $28
Q3 2008 $21
Q2 2008 $20
Q1 2008 $20
Q4 2007 $66
Q3 2007 $56
Q2 2007 $66
Q1 2007 $85
Q4 2006 $70
Q3 2006 $59
Q2 2006 $60
Q1 2006 $29
Q4 2005 $33
Q3 2005 $36
Q2 2005 $29
Q1 2005 $28
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $5.516B $1.193B
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company's wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $47.457B 31.54
Takeda Pharmaceutical (TAK) Japan $28.357B 10.49
Grifols (GRFS) Spain $12.830B 15.68
Ionis Pharmaceuticals (IONS) United States $10.102B 32.30
Sage Therapeutics (SAGE) United States $7.758B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.328B 10.49
Neurocrine Biosciences (NBIX) United States $7.158B 461.35
Catalent (CTLT) United States $6.403B 26.81
Tilray (TLRY) United States $4.740B 0.00
United Therapeutics (UTHR) United States $4.387B 7.46
Taro Pharmaceutical Industries (TARO) Israel $4.097B 13.19
FibroGen (FGEN) United States $4.039B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $3.793B 0.00
Portola Pharmaceuticals (PTLA) United States $2.252B 0.00
PTC Therapeutics (PTCT) United States $2.099B 0.00
USANA Health Sciences (USNA) United States $1.921B 16.12
Heron Therapeutics (HRTX) United States $1.837B 0.00
Aerie Pharmaceuticals (AERI) United States $1.799B 0.00
Xencor (XNCR) United States $1.765B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.738B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $1.712B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.668B 20.77
Madrigal Pharmaceuticals (MDGL) United States $1.627B 0.00
Endo (ENDP) Ireland $1.598B 2.46
Zogenix (ZGNX) United States $1.534B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.518B 131.46
Corcept Therapeutics (CORT) United States $1.372B 19.93
Tricida (TCDA) United States $1.330B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.279B 0.00
Esperion Therapeutics (ESPR) United States $1.098B 0.00
Spectrum Pharmaceuticals (SPPI) United States $1.066B 0.00
TherapeuticsMD (TXMD) United States $1.020B 0.00
Radius Health (RDUS) United States $0.980B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.873B 0.00
Akebia Therapeutics (AKBA) United States $0.786B 0.00
CannTrust Holdings (CTST) Canada $0.751B 0.00
ArQule (ARQL) United States $0.713B 0.00
ChemoCentryx (CCXI) United States $0.700B 0.00
Dermira (DERM) United States $0.619B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.577B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.573B 0.00
Odonate Therapeutics (ODT) United States $0.573B 0.00
Forty Seven (FTSV) United States $0.559B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.546B 0.00
GlycoMimetics (GLYC) United States $0.523B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.460B 23.76
Corbus Pharmaceuticals Holdings (CRBP) United States $0.454B 0.00
Translate Bio (TBIO) United States $0.452B 0.00
Collegium Pharmaceutical (COLL) United States $0.451B 0.00
KalVista Pharmaceuticals (KALV) United States $0.440B 0.00
TCR2 THERAPTCS (TCRR) United States $0.439B 0.00
Siga Technologies (SIGA) United States $0.430B 0.00
OptiNose (OPTN) United States $0.408B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.396B 0.00
Flexion Therapeutics (FLXN) United States $0.388B 0.00
Aptorum Group (APM) China $0.388B 0.00
ImmunoGen (IMGN) United States $0.368B 0.00
Mast Therapeutics (SVRA) United States $0.334B 0.00
Harpoon Therapy (HARP) United States $0.317B 0.00
CASI Pharmaceuticals (CASI) United States $0.316B 0.00
Karyopharm Therapeutics (KPTI) United States $0.282B 0.00
Lannett Co Inc (LCI) United States $0.281B 2.61
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.276B 10.21
Minerva Neurosciences (NERV) United States $0.274B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.274B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.266B 0.00
Xeris Pharmaceuticals (XERS) United States $0.259B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.251B 0.00
Calithera Biosciences (CALA) United States $0.241B 0.00
Dova Pharmaceuticals (DOVA) United States $0.233B 0.00
Molecular Templates (MTEM) United States $0.231B 0.00
Aclaris Therapeutics (ACRS) United States $0.228B 0.00
Concert Pharmaceuticals (CNCE) United States $0.222B 0.00
Ardelyx (ARDX) United States $0.212B 0.00
Affimed (AFMD) Germany $0.209B 0.00
MEI Pharma (MEIP) United States $0.208B 0.00
Aldeyra Therapeutics (ALDX) United States $0.204B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.201B 0.00
Opexa Therapeutics (ACER) United States $0.200B 0.00
Galectin Therapeutics (GALT) United States $0.196B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.194B 0.00
Taiwan Liposome, Unsponsored ADR (TLC) Taiwan $0.186B 0.00
Recro Pharma (REPH) United States $0.184B 0.00
Jounce Therapeutics (JNCE) United States $0.184B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.183B 0.00
Nature's Sunshine Products (NATR) United States $0.182B 189.00
ElectroCore (ECOR) United States $0.182B 0.00
Neon Therapeutics (NTGN) United States $0.177B 0.00
Majesco Entertainment (PTE) United States $0.174B 0.00
Redhill Biopharma (RDHL) Israel $0.172B 0.00
Aratana Therapeutics (PETX) United States $0.171B 0.00
IMV INC (IMV) Canada $0.170B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.168B 0.00
Tyme Technologies (TYME) United States $0.158B 0.00
Aquestive Therapeutics (AQST) United States $0.157B 0.00
Ocular Therapeutix (OCUL) United States $0.156B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.136B 0.00
MediWound (MDWD) Israel $0.132B 0.00
China SXT Pharmaceuticals (SXTC) China $0.119B 0.00
Iterum Therapeutics (ITRM) Ireland $0.114B 0.00
ProNAi Therapeutics (SRRA) Canada $0.109B 0.00
Cardiome Pharma (CORV) Canada $0.106B 0.00
Nivalis Therapeutics (ALPN) United States $0.105B 0.00
Natural Alternatives (NAII) United States $0.098B 9.62
Neos Therapeutics (NEOS) United States $0.097B 0.00
Zafgen (ZFGN) United States $0.097B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.094B 0.00
Adherex Technologies (FENC) United States $0.094B 0.00
DURECT (DRRX) United States $0.093B 0.00
Champions Oncology (CSBR) United States $0.092B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.091B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.090B 0.00
Infinity Pharmaceuticals (INFI) United States $0.089B 0.00
Bio Blast Pharma (ENLV) Israel $0.083B 0.00
SCYNEXIS (SCYX) United States $0.083B 0.00
Otonomy (OTIC) United States $0.079B 0.00
Genocea Biosciences (GNCA) United States $0.078B 0.00
Avenue Therapeutics (ATXI) United States $0.075B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.072B 0.00
Capnia (SLNO) United States $0.064B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.057B 0.00
CTI BioPharma (CTIC) United States $0.056B 0.00
Forward Pharma (FWP) Denmark $0.056B 0.00
Melinta Therapeutics (MLNT) United States $0.049B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.048B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.048B 0.00
Bio-Path Holdings (BPTH) United States $0.048B 0.00
Lipocine (LPCN) United States $0.044B 0.00
KemPharm (KMPH) United States $0.043B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.043B 0.00
ContraFect (CFRX) United States $0.042B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.040B 0.00
BioLineRx (BLRX) Israel $0.040B 0.00
Mannatechorporated (MTEX) United States $0.040B 0.00
Heat Biologics (HTBX) United States $0.038B 0.00
ProPhase Labs (PRPH) United States $0.035B 0.00
HANCOCK JAFFE (HJLI) United States $0.034B 0.00
Shineco (TYHT) China $0.029B 4.88
Summit Therapeutics (SMMT) United Kingdom $0.026B 3.47
PharmAthene (ALT) United States $0.025B 0.00
Citius Pharmaceuticals (CTXR) United States $0.024B 0.00
Jaguar Animal Health (JAGX) United States $0.024B 0.00
Achieve Life Sciences (ACHV) United States $0.024B 0.00
Biomerica (BMRA) United States $0.024B 0.00
Onconova Therapeutics (ONTX) United States $0.022B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.020B 0.00
NOVAN INC (NOVN) United States $0.020B 0.00
Cyanotech (CYAN) United States $0.020B 0.00
Pain Therapeutics (SAVA) United States $0.019B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.017B 0.00
Xenetic Biosciences (XBIO) United States $0.016B 0.00
ESSA Pharma (EPIX) Canada $0.015B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.014B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.013B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.013B 4.07
Regulus Therapeutics (RGLS) United States $0.012B 0.00
PRECISION THERAPEUTICS INC (AIPT) United States $0.012B 0.00
Achaogen (AKAO) United States $0.011B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.010B 0.00
RXi Pharmaceuticals (PHIO) United States $0.010B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.009B 0.00
Trillium Therapeutics (TRIL) Canada $0.009B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.008B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.006B 0.00
VAXART, INC (VXRT) United States $0.006B 0.00
Midatech Pharma (MTP) United Kingdom $0.006B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00